 - Patients must have histologically confirmed diagnosis of primary malignant glioma glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma, or anaplastic oligodendroglioma who are either chemotherapy naïve or non-naïve and scheduled to receive IrinotecanBevacizumab chemotherapy. 